Latest News

Date Title Topic
01 Jun 2017 FDA Accepts for Priority Review Application for Nivolumab in Previously Treated Hepatocellular Carcinoma Gastrointestinal cancers - Cancer Immunology and Immunotherapy
31 May 2017 Press Release: ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution Bioethics, legal and economic issues
31 May 2017 FDA Broadens Ceritinib Indication to Previously Untreated ALK-positive Metastatic NSCLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 May 2017 NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 May 2017 FDA Grants Accelerated Approval to Pembrolizumab for Unresectable or Metastatic MSI-H or dMMR Solid Tumours Cancer Immunology and Immunotherapy
26 May 2017 Withdrawal of the Marketing Authorisation Application for Vosaroxin Haematologic malignancies - Anticancer agents & Biologic therapy
Track Chairs' Top Picks
24 May 2017 EMA Completes an Arbitration Procedure for Dexrazoxane Palliative and supportive care
22 May 2017 EMA Adopts a Negative Opinion for Anamorelin Hydrochloride Palliative and supportive care - Lung and other thoracic tumours
22 May 2017 EMA Adopts a New Indication for Ceritinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
19 May 2017 FDA Grants Approval to Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
18 May 2017 EMA Launches Public Consultations to Revise Three Scientific Guidelines Bioethics, legal and economic issues
17 May 2017 NaviCam for Diagnosing Gastrointestinal Tract Conditions Diagnosis, Imaging and Staging
16 May 2017 ESMO - EIU Report on Shortages of Inexpensive, Essential Cancer Medicines Bioethics, legal and economic issues
16 May 2017 Severe Skin Reactions from Pembrolizumab Palliative and supportive care - Cancer Immunology and Immunotherapy